>

Meet our science and scientists at SITC and EORTC

Members from the NanoSyrinx team will be on the road over the coming weeks presenting exciting data from our internal developments and recent collaborations.

If you’d like to learn more about our science and meet some of the talented folks responsible for it, come along to the sessions below. A copy of the poster can also be viewed below.

EORTC

ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics (23rd-25th October)

https://event.eortc.org/ena2024/

Barcelona International Convention Center

The EORTC symposium is focused on drug development and translational research with main topics including target selection/validation, and the impact of new discoveries in molecular biology.

Come and say hello!

Poster Session: “Drug Delivery”

When: Friday, 25 October 2024, 09:00 – 15:00

Abstract # 367 / Poster board number: PB355.

SITC

Society for Immunotherapy of Cancer 2024 (6th-10th November)

https://www.sitcancer.org/2024/home

George R. Brown Convention Center in Houston, TX

SITC delves in to the cutting edge world of cancer immunotherapies and related topics, featuring innovations across the maturity spectrum from early stage to clinical trials.

Come and say hello!

When: Saturday, 09 November 2024

Abstract/Poster number: 810

Read more news

Dr Valentina Galli

NanoSyrinx strengthens senior R&D team

Appointments of Dr Valentina Galli as Associate Research Director, Translational Biology, and Steve Ruscoe as Principal Scientist, Process Development Drug delivery and process development expertise further expands the Company’s R&D capabilities Coventry, UK, 21st January 2025: NanoSyrinx, a synthetic biology company developing Nanosyringes as a novel platform for targeted intracellular delivery of biologic therapeutics, today […]

Read more

Meet our science and scientists at SITC and EORTC

Members from the NanoSyrinx team will be on the road over the coming weeks presenting exciting data from our internal developments and recent collaborations. If you’d like to learn more about our science and meet some of the talented folks responsible for it, come along to the sessions below. A copy of the poster can […]

Read more
Dr Edwin Moses, Chairman NanoSyrinx

NanoSyrinx closes £10 million GBP financing and appoints Dr. Edwin Moses as Chairman

Round co-led by BGF, Octopus Ventures and M Ventures, with support from new corporate investor, Eli Lilly and Company, and existing investors, IQ Capital and Meltwind Appointment of Edwin Moses as Chairman to support the leadership team in maximising the value of the technology platform Novel “nanosyringe” platform can deliver complex biologic payloads selectively and […]

Read more